Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that GPT-4o demonstrated high concordance with in-person and image-based provider assessments in generating SALT scores for alopecia areata, suggesting its potential as an adjunct tool in clinical practice for automating these assessments.

This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.

This study found that mouse and human protransglutaminase 3 enzymes require calcium-regulated activation for their role in later stages of cell envelope formation in the epidermis and hair follicle.

Androgenetic alopecia is the main reason people lose hair, and while some think it's normal, others find it abnormal and want treatment.

This study found that Gnαs and Gnα11 proteins were significantly more expressed in the skin of black sheep compared to white sheep, suggesting their role in coat color regulation.

In this study, compound glycyrrhizin promoted hair regrowth in a testosterone-induced alopecia mouse model and increased human hair dermal papilla cell proliferation, likely through activating the Wnt/β-catenin pathway.

This study identified eight genetic markers associated with androgenetic alopecia, suggesting that these SNPs could influence individualized therapeutic responses and highlight the need for personalized treatment strategies.

This study found that men with adrenomyeloneuropathy often experience diffuse hair loss and severe male-pattern baldness, potentially due to the X-linked ALD mutation's role in androgenetic alopecia's genetic spectrum.

This study found that in male patients with androgenic alopecia, individuals with certain glutathione S-transferase gene polymorphisms exhibited higher oxidative stress and lower antioxidant capacity, although differences were not statistically significant, and oxidative stress appeared to increase with the progression of alopecia stages.

This study demonstrated that polynucleotide gel injections effectively reduced hair shedding and increased hair thickness in both men and women with androgenetic alopecia, while maintaining a high safety profile and patient satisfaction.

This study found that variations in (CAG)n and (GGN)n polymorphisms in the androgen receptor gene appear to influence symptom severity in men with post-finasteride syndrome.

This study observed that atopic dermatitis severity was associated with higher eosinophil counts and FLG variants, suggesting distinct endotypes that may require tailored treatment approaches.

This review discusses recent research on the use of concentrated growth factor (CGF) for treating androgenetic alopecia, highlighting its potential to enhance hair regrowth and improve hair density but noting the need for high-quality clinical trials.

This study reviews the interplay between endocrine factors and genetic predisposition in androgenetic alopecia, highlighting various treatment options, including new medical, surgical, and light-based therapies, though some remain relatively unexplored.

This study found that multidisciplinary group medical visits for patients with alopecia areata improved patient satisfaction, knowledge, and access to care at Lahey Hospital and Medical Center.

This study investigated AGA professionals' perspectives and found that 42% were misled by commercial influences, underestimated these biases' extent, and faced ethical challenges in treatment due to societal pressures and misinformation, highlighting a need for evidence-based guidance and research scrutiny tools.

This study found that in the dorsal horn's lamina III, most afferent boutons form synapses with presynaptic boutons immunoreactive for GABA and/or glycine, influencing sensory pathways.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This study found six new genetic factors linked to early-onset androgenetic alopecia and its association with increased risk of Parkinson's disease and decreased fertility.

This study found that men with early-onset androgenetic alopecia had larger prostate volumes and lower urinary flow rates compared to those without the condition, suggesting a potential link between AGA and urinary symptoms.

This study found that a novel nano-engineered platform, PCA, significantly promoted hair regeneration in an androgenetic alopecia mouse model by enhancing angiogenesis and hair follicle stem cell proliferation, showing promise for future hair regrowth treatments.

AGA patients have higher rates of metabolic syndrome and carotid atheromatosis, suggesting early screening and prevention is important.

This study found that men with early-onset male pattern alopecia did not significantly differ from healthy individuals in cardiovascular and metabolic measures, but hsCRP and galectin-3 were linked to cardiovascular risk factors in those with the condition.

In this study, researchers found that the G(S)alpha subunit is strongly expressed in neonatal mouse hair follicles, indicating it may play a role in initiating follicle growth.

This study found that serum 8-Hydroxydeoxyguanosine levels were significantly higher in alopecia areata patients compared to healthy controls, suggesting its potential as a diagnostic and prognostic biomarker for the condition.

This study found that a specific genetic mutation in the Fgf5 gene may contribute to the long-hair trait in Angora rabbits by reducing the binding capacity of the FGF5 protein.

This review discusses the androgen-dependent and genetic factors of androgenetic alopecia, highlighting differences in its manifestation between men and women, and reports no new clinical results.

In this study, patients with androgenetic alopecia showed no difference in insulin resistance or prevalence of metabolic syndrome but had higher cardiovascular risk due to increased inflammatory markers and lipoprotein(a) levels.

This study developed a testosterone-induced androgenetic alopecia model in BALB/c mice, finding that a 0.075 ml testosterone injection best replicated the dermal and hair follicle conditions of AGA patients, providing a promising tool for future drug testing and research into AGA therapies.

The study found that patients with androgenetic alopecia had higher serum GPER-1 levels, which were associated with disease severity and duration, indicating a potential estrogen-independent role of GPER-1 in the condition's pathogenesis.